83898-43-5

Basic information

• Product Name: ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate
• Synonyms: ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate;3-Hydroxy-4,4-dimethoxy-1-piperidinecarboxylic acid ethyl ester;3-Hydroxy-4,4-dimethoxypiperidine-1-carboxylic acid ethyl ester;Einecs 281-253-6
• CAS NO: 83898-43-5
• Molecular Formula: C₁₀H₁₉NO₅
• Molecular Weight: 233.26156
• EINECS: 281-253-6
• Mol File: 83898-43-5.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 320.5°C at 760 mmHg
• Flash Point: 147.6°C
• Appearance: /
• Density: 1.18g/cm³
• Vapor Pressure: 2.57E-05mmHg at 25°C
• Refractive Index: 1.492
• CAS DataBase Reference: ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate(83898-43-5)
• EPA Substance Registry System: ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate(83898-43-5)

Safety Data

• Hazardous Substances Data: 83898-43-5(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H19NO5/c1-4-16-9(13)11-6-5-10(14-2,15-3)8(12)7-11/h8,12H,4-7H2,1-3H3

Upstream product

• 124-41-4 sodium methylate 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 95629-02-0 ethyl 3-bromo-4-oxo-1-piperidinecarboxylate 
• 67-56-1 methanol 

Downstream Products

• 83863-73-4 (-)-ethyl 3,4,4-trimethoxy-1-piperidinecarboxylate 
• 907543-85-5 ethyl (3R,4S)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 907543-86-6 ethyl (3S,4R)-4-(benzylamino)-3-methoxypiperidine-1-carboxylate 
• 882737-71-5 ethyl (3S,4R)-4-amino-3-methoxypiperidine-1-carboxylate 
• 907572-18-3 ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate 
• 83863-72-3 (-)-ethyl 3-methoxy-4-oxo-1-piperidine-carboxylate 
• 86717-78-4 ethyl 3-ethoxy-4-oxo-piperidine-1-carboxylate 
• 128225-42-3 cis(+/-) ethyl 4-amino-3-methoxypiperidine-1-carboxylate 

Relevant articles and documents

LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES

Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.

Optimization of pyrrolamide topoisomerase II inhibitors toward identification of an antibacterial clinical candidate (AZD5099)

AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF

This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.